

Ontologies Classes Object Properties Data Properties Annotation Properties Individuals Datatypes Clouds

Class: Disparities_in_Incidence

Annotations (4)

- `rdfs:comment` "Asian Americans or Pacific Islanders with lung cancer were 16% less likely to be diagnosed early and 3% more likely to not receive any treatment compared to white Americans. However, unlike other groups, they were 16% more likely to receive surgical treatment and equally likely to survive five years compared to white Americans."
- `rdfs:comment` "Black Americans with lung cancer were 15% less likely to be diagnosed early, 19% less likely to receive surgical treatment, 10% more likely to not receive any treatment, and 12% less likely to survive five years compared to white Americans."
- `rdfs:comment` "Indigenous Peoples (American Indians/Alaska Natives) with lung cancer were 13% less likely to be diagnosed early, 21% less likely to receive surgical treatment, 11% more likely to not receive any treatment, and 23% less likely to survive five years compared to white Americans."
- `rdfs:comment` "Latino Americans with lung cancer were 15% less likely to be diagnosed early, equally likely to receive surgical treatment, 28% more likely to not receive any treatment, and 25% less likely to survive five years compared to white Americans."

Superclasses (1)

- Cultural_LC

Disjoints (689)

'\Abraxane_(Paclitaxel_Albumin-stabilized_Nanoparticle_Formulation)_\'', '\Afinitor_(Everolimus)_\'', '\Afinitor_Disperz_(Everolimus)_\'', '\Alecensa_(Alectinib)_\'', '\Alimta_(Pemetrexed_Disodium)_\'', '\Alunbrig_(Brigatinib)_\'', '\Alymsys_(Bevacizumab)_\'', '\Avastin_(Bevacizumab)_\'', '\Cyramza_(Ramucirumab)_\'', '\Enhertu_(Fam-Trastuzumab_Deruxtecan-nxki)_\'', '\Etopophos_(Etoposide_Phosphate)_\'', '\Exkivity_(Mobocertinib_Succinate)_\'', '\Gavreto_(Pralsetinib)_\'', '\Gemzar_(Gemcitabine_Hydrochloride)_\'', '\Gilotrif_(Afatinib_Dimaleate)_\'', '\Hycamtin_(Topotecan_Hydrochloride)_\'', '\Imfinzi_(Durvalumab)_\'', '\Imjudo_(Tremelimumab-actl)_\'', '\Infugem_(Gemcitabine_Hydrochloride)_\'', '\Iressa_(Gefitinib)_\'', '\Keytruda_(Pembrolizumab)_\'', '\Krazati_(Adagrasib)_\'', '\Libtayo_(Cemiplimab-rwlc)_\'', '\Lorbrena_(Lorlatinib)_\'', '\Lumakras_(Sotorasib)_\'', '\Mekinist_(Trametinib_Dimethyl_Sulfoxide)_\'', '\Mvasi_(Bevacizumab)_\'', '\Opdivo_(Nivolumab)_\'', '\Portrazza_(Necitumumab)_\'', '\Retevmo_(Selpercatinib)_\'', '\Rozlytrek_(Entrectinib)_\'', '\Rybrevant_(Amivantamab-vmjw)_\'', '\Tabrecta_(Capmatinib_Hydrochloride)_\'', '\Tafinlar_(Dabrafenib_Mesylate)_\'', '\Tagrisso_(Osimertinib_Mesylate)_\'', '\Taxotere_(Docetaxel)_\'', '\Tecentriq_(Atezolizumab)_\'', '\Tepmetko_(Tepotinib_Hydrochloride)_\'', '\Trexall_(Methotrexate_Sodium)_\'', '\Vizimpro_(Dacomitinib)_\'', '\Xalkori_(Crizotinib)_\'', '\Yervoy_(Ipilimumab)_\'', '\Zirabev_(Bevacizumab)_\'', '\Zykadia_(Ceritinib)_\'', 4A_NSCLC, 4B_NSCLC, Adagrasib_, Adherence_Based_on_Socioeconomics_LC, Adherence_Factors_LC, Adverse_Reactions_ABRAX, Adverse_Reactions_ADAGR, Adverse_Reactions_AFATI, Adverse_Reactions_AFINI, Adverse_Reactions_AFINIT, Adverse_Reactions_ALECE, Adverse_Reactions_ALIMT, Adverse_Reactions_ALUNB, Adverse_Reactions_ALYMS, Adverse_Reactions_AMIVA, Adverse_Reactions_ATEZO, Adverse_Reactions_AVAST, Adverse_Reactions_BRIGA, Adverse_Reactions_CAPMA, Adverse_Reactions_CEMIP, Adverse_Reactions_CYRAM, Adverse_Reactions_DOXOR, Adverse_Reactions_DURVA, Adverse_Reactions_ENHER, Adverse_Reactions_ENTRE, Adverse_Reactions_ERLOT, Adverse_Reactions_ETOP, Adverse_Reactions_ETOPO, Adverse_Reactions_EXKIV, Adverse_Reactions_GAVRE, Adverse_Reactions_GEFIT, Adverse_Reactions_GEMZA, Adverse_Reactions_GILOT, Adverse_Reactions_HYCAM, Adverse_Reactions_IMFIN, Adverse_Reactions_IMJUD, Adverse_Reactions_INFUG, Adverse_Reactions_IRESS, Adverse_Reactions_KEYTR, Adverse_Reactions_KRAZA, Adverse_Reactions_LIBTA, Adverse_Reactions_LORBR, Adverse_Reactions_LUMAK, Adverse_Reactions_LURB, Adverse_Reactions_MEKIN, Adverse_Reactions_METH, Adverse_Reactions_MVASI, Adverse_Reactions_OPDIV, Adverse_Reactions_PORTR, Adverse_Reactions_RAMUC, Adverse_Reactions_RETEV, Adverse_Reactions_ROZLY, Adverse_Reactions_RYBRE, Adverse_Reactions_SELPE, Adverse_Reactions_SOTOR, Adverse_Reactions_TABRE, Adverse_Reactions_TAFIN, Adverse_Reactions_TAGRIS, Adverse_Reactions_TAXOT, Adverse_Reactions_TECEN, Adverse_Reactions_TEPME, Adverse_Reactions_TOPO, Adverse_Reactions_TRAME, Adverse_Reactions_TREME, Adverse_Reactions_TREXA, Adverse_Reactions_VINOR, Adverse_Reactions_VIZIM, Adverse_Reactions_XALKO, Adverse_Reactions_YERVO, Adverse_Reactions_ZIRAB, Adverse_Reactions_ZYKAD, Afatinib_Dimaleate_, Age, Air_Pollution, Amivantamab-vmjw_, Atezolizumab_, Behavioral_Factors_LC, Beta_Carotene_Supplements_LC, Bio_Sensors_LC, Biological_Effects_LC, Breathalyzer_LC, Breathing_LC, Brigatinib_,

Capmatinib_Hydrochloride_, Causes_and_Risks_LC, Cemiplimab-rwlc_, Chemical_Sensors_LC,
 Choosing_Quality_of_Life_-_Reasons_People_Forego_Treatment, Choosing_Survival_-_
 Deciding_to_Undergo_Treatment, Clinical_Factors_LC, Complications_LC, Contraindications_ABRAX,
 Contraindications_ADAGR, Contraindications_AFATI, Contraindications_AFINI, Contraindications_AFINIT,
 Contraindications_ALECE, Contraindications_ALIMT, Contraindications_ALUNB, Contraindications_ALYMS,
 Contraindications_AMIVA, Contraindications_ATEZO, Contraindications_AVAST, Contraindications_BRIGA,
 Contraindications_CAPMA, Contraindications_CEMIP, Contraindications_CYRAM, Contraindications_DOXOR,
 Contraindications_DURVA, Contraindications_ENHER, Contraindications_ENTRE, Contraindications_ERLOT,
 Contraindications_ETOP, Contraindications_ETOPO, Contraindications_EXKIV, Contraindications_GAVRE,
 Contraindications_GEFIT, Contraindications_GEMZA, Contraindications_GILOT, Contraindications_HYCAM,
 Contraindications_IMFIN, Contraindications_IMJUD, Contraindications_INFUG, Contraindications_IRESS,
 Contraindications_KEYTR, Contraindications_KRAZA, Contraindications_LIBTA, Contraindications_LORBR,
 Contraindications_LUMAK, Contraindications_LURB, Contraindications_MEKIN, Contraindications_METH,
 Contraindications_MVASI, Contraindications_OPDIV, Contraindications_PORTR, Contraindications_RAMUC,
 Contraindications_RETEV, Contraindications_ROZLY, Contraindications_RYBRE, Contraindications_SELPE,
 Contraindications_SOTOR, Contraindications_TABRE, Contraindications_TAFIN, Contraindications_TAGRIS,
 Contraindications_TAXOT, Contraindications_TECEN, Contraindications_TEPME, Contraindications_TOPO,
 Contraindications_TRAME, Contraindications_TREME, Contraindications_TREXA, Contraindications_VINOR,
 Contraindications_VIZIM, Contraindications_XALKO, Contraindications_YERVO, Contraindications_ZIRAB,
 Contraindications_ZYKAD, Cultural_Beliefs_and_Perceptions, Degrees_of_Smoking_LC, Diet_LC,
Disparities_in_Incidence, Dosage_and_Administration_ABRAX, Dosage_and_Administration_ADAGR,
 Dosage_and_Administration_AFATI, Dosage_and_Administration_AFINI, Dosage_and_Administration_AFINIT,
 Dosage_and_Administration_ALECE, Dosage_and_Administration_ALIMT, Dosage_and_Administration_ALUNB,
 Dosage_and_Administration_ALYMS, Dosage_and_Administration_AMIVA, Dosage_and_Administration_ATEZO,
 Dosage_and_Administration_AVAST, Dosage_and_Administration_BRIGA, Dosage_and_Administration_CAPMA,
 Dosage_and_Administration_CEMIP, Dosage_and_Administration_CYRAM, Dosage_and_Administration_DOXOR,
 Dosage_and_Administration_DURVA, Dosage_and_Administration_ENHER, Dosage_and_Administration_ENTRE,
 Dosage_and_Administration_ERLOT, Dosage_and_Administration_ETOP, Dosage_and_Administration_ETOPO,
 Dosage_and_Administration_EXKIV, Dosage_and_Administration_GAVRE, Dosage_and_Administration_GEFIT,
 Dosage_and_Administration_GEMZA, Dosage_and_Administration_GILOT, Dosage_and_Administration_HYCAM,
 Dosage_and_Administration_IMFIN, Dosage_and_Administration_IMJUD, Dosage_and_Administration_INFUG,
 Dosage_and_Administration_IRESS, Dosage_and_Administration_KEYTR, Dosage_and_Administration_KRAZA,
 Dosage_and_Administration_LIBTA, Dosage_and_Administration_LORBR, Dosage_and_Administration_LUMAK,
 Dosage_and_Administration_LURB, Dosage_and_Administration_MEKIN, Dosage_and_Administration_METH,
 Dosage_and_Administration_MVASI, Dosage_and_Administration_OPDIV, Dosage_and_Administration_PORTR,
 Dosage_and_Administration_RAMUC, Dosage_and_Administration_RETEV, Dosage_and_Administration_ROZLY,
 Dosage_and_Administration_RYBRE, Dosage_and_Administration_SELPE, Dosage_and_Administration_SOTOR,
 Dosage_and_Administration_TABRE, Dosage_and_Administration_TAFIN, Dosage_and_Administration_TAGRIS,
 Dosage_and_Administration_TAXOT, Dosage_and_Administration_TECEN, Dosage_and_Administration_TEPME,
 Dosage_and_Administration_TOPO, Dosage_and_Administration_TRAME, Dosage_and_Administration_TREME,
 Dosage_and_Administration_TREXA, Dosage_and_Administration_VINOR, Dosage_and_Administration_VIZIM,
 Dosage_and_Administration_XALKO, Dosage_and_Administration_YERVO, Dosage_and_Administration_ZIRAB,
 Dosage_and_Administration_ZYKAD, Dosage_Forms_and_Strengths_ABRAX,
 Dosage_Forms_and_Strengths_ADAGR, Dosage_Forms_and_Strengths_AFATI,
 Dosage_Forms_and_Strengths_AFINI, Dosage_Forms_and_Strengths_AFINIT,
 Dosage_Forms_and_Strengths_ALECE, Dosage_Forms_and_Strengths_ALIMT,
 Dosage_Forms_and_Strengths_ALUNB, Dosage_Forms_and_Strengths_ALYMS,
 Dosage_Forms_and_Strengths_AMIVA, Dosage_Forms_and_Strengths_ATEZO,
 Dosage_Forms_and_Strengths_AVAST, Dosage_Forms_and_Strengths_BRIGA,
 Dosage_Forms_and_Strengths_CAPMA, Dosage_Forms_and_Strengths_CEMIP,
 Dosage_Forms_and_Strengths_CYRAM, Dosage_Forms_and_Strengths_DOXOR,
 Dosage_Forms_and_Strengths_DURVA, Dosage_Forms_and_Strengths_ENHER,
 Dosage_Forms_and_Strengths_ENTRE, Dosage_Forms_and_Strengths_ERLOT,
 Dosage_Forms_and_Strengths_ETOP, Dosage_Forms_and_Strengths_ETOPO,
 Dosage_Forms_and_Strengths_EXKIV, Dosage_Forms_and_Strengths_GAVRE,
 Dosage_Forms_and_Strengths_GEFIT, Dosage_Forms_and_Strengths_GEMZA,
 Dosage_Forms_and_Strengths_GILOT, Dosage_Forms_and_Strengths_HYCAM,
 Dosage_Forms_and_Strengths_IMFIN, Dosage_Forms_and_Strengths_IMJUD,
 Dosage_Forms_and_Strengths_INFUG, Dosage_Forms_and_Strengths_IRESS,
 Dosage_Forms_and_Strengths_KEYTR, Dosage_Forms_and_Strengths_KRAZA,
 Dosage_Forms_and_Strengths_LIBTA, Dosage_Forms_and_Strengths_LORBR,
 Dosage_Forms_and_Strengths_LUMAK, Dosage_Forms_and_Strengths_LURB,
 Dosage_Forms_and_Strengths_MEKIN, Dosage_Forms_and_Strengths_METH,
 Dosage_Forms_and_Strengths_MVASI, Dosage_Forms_and_Strengths_OPDIV,
 Dosage_Forms_and_Strengths_PORTR, Dosage_Forms_and_Strengths_RAMUC,

Dosage_Forms_and_Strengths_RETEV, Dosage_Forms_and_Strengths_ROZLY,
 Dosage_Forms_and_Strengths_RYBRE, Dosage_Forms_and_Strengths_SELPE,
 Dosage_Forms_and_Strengths_SOTOR, Dosage_Forms_and_Strengths_TABRE,
 Dosage_Forms_and_Strengths_TAFIN, Dosage_Forms_and_Strengths_TAGRIS,
 Dosage_Forms_and_Strengths_TAXOT, Dosage_Forms_and_Strengths_TECEN,
 Dosage_Forms_and_Strengths_TEPME, Dosage_Forms_and_Strengths_TOPO,
 Dosage_Forms_and_Strengths_TRAME, Dosage_Forms_and_Strengths_TREME,
 Dosage_Forms_and_Strengths_TREXA, Dosage_Forms_and_Strengths_VINOR,
 Dosage_Forms_and_Strengths_VIZIM, Dosage_Forms_and_Strengths_XALKO,
 Dosage_Forms_and_Strengths_YERVO, Dosage_Forms_and_Strengths_ZIRAB,
 Dosage_Forms_and_Strengths_ZYKAD, Doxorubicin_Hydrochloride_, Drug_Interactions_ABRAX,
 Drug_Interactions_ADAGR, Drug_Interactions_AFATI, Drug_Interactions_AFINI, Drug_Interactions_AFINIT,
 Drug_Interactions_ALECE, Drug_Interactions_ALIMT, Drug_Interactions_ALUNB, Drug_Interactions_ALYMS,
 Drug_Interactions_AMIVA, Drug_Interactions_ATEZO, Drug_Interactions_AVAST, Drug_Interactions_BRIGA,
 Drug_Interactions_CAPMA, Drug_Interactions_CEMIP, Drug_Interactions_CYRAM, Drug_Interactions_DOXOR,
 Drug_Interactions_DURVA, Drug_Interactions_ENHER, Drug_Interactions_ENTRE, Drug_Interactions_ERLOT,
 Drug_Interactions_ETOP, Drug_Interactions_ETOPO, Drug_Interactions_EXKIV, Drug_Interactions_GAVRE,
 Drug_Interactions_GEFIT, Drug_Interactions_GEMZA, Drug_Interactions_GILOT, Drug_Interactions_HYCAM,
 Drug_Interactions_IMFIN, Drug_Interactions_IMJUD, Drug_Interactions_INFUG, Drug_Interactions_IRESS,
 Drug_Interactions_KEYTR, Drug_Interactions_KRAZA, Drug_Interactions_LIBTA, Drug_Interactions_LORBR,
 Drug_Interactions_LUMAK, Drug_Interactions_LURB, Drug_Interactions_MEKIN, Drug_Interactions_METH,
 Drug_Interactions_MVASI, Drug_Interactions_OPDIV, Drug_Interactions_PORTR, Drug_Interactions_RAMUC,
 Drug_Interactions_RETEV, Drug_Interactions_ROZLY, Drug_Interactions_RYBRE, Drug_Interactions_SELPE,
 Drug_Interactions_SOTOR, Drug_Interactions_TABRE, Drug_Interactions_TAFIN, Drug_Interactions_TAGRIS,
 Drug_Interactions_TAXOT, Drug_Interactions_TECEN, Drug_Interactions_TEPME, Drug_Interactions_TOPO,
 Drug_Interactions_TRAME, Drug_Interactions_TREME, Drug_Interactions_TREXA, Drug_Interactions_VINOR,
 Drug_Interactions_VIZIM, Drug_Interactions_XALKO, Drug_Interactions_YERVO, Drug_Interactions_ZIRAB,
 Drug_Interactions_ZYKAD, Durvalumab_, E-Cigarettes_LC, Electronic_Sensors_LC, Emotions_LC,
 End_of_Life_Decisions, Entrectinib_, Environmental_Factors_LC, Enzymatic_Sensors_LC,
 Erlotinib_Hydrochloride_, Etoposide_, Exercise_LC, Extensive_Stage_SCLC, Family_History_LC, Gefitinib_,
 Genomic_Sequencing_LC, Geographical_Location, Habits_LC, HIV_Infection_LC, Immunosensors_LC,
 Increased_Susceptibility_LC, Indications_and_Usage_ABRAX, Indications_and_Usage_ADAGR,
 Indications_and_Usage_AFATI, Indications_and_Usage_AFINI, Indications_and_Usage_AFINIT,
 Indications_and_Usage_ALECE, Indications_and_Usage_ALIMT, Indications_and_Usage_ALUNB,
 Indications_and_Usage_ALYMS, Indications_and_Usage_AMIVA, Indications_and_Usage_ATEZO,
 Indications_and_Usage_AVAST, Indications_and_Usage_BRIGA, Indications_and_Usage_CAPMA,
 Indications_and_Usage_CEMIP, Indications_and_Usage_CYRAM, Indications_and_Usage_DOXOR,
 Indications_and_Usage_DURVA, Indications_and_Usage_ENHER, Indications_and_Usage_ENTRE,
 Indications_and_Usage_ERLOT, Indications_and_Usage_ETOP, Indications_and_Usage_ETOPO,
 Indications_and_Usage_EXKIV, Indications_and_Usage_GAVRE, Indications_and_Usage_GEFIT,
 Indications_and_Usage_GEMZA, Indications_and_Usage_GILOT, Indications_and_Usage_HYCAM,
 Indications_and_Usage_IMFIN, Indications_and_Usage_IMJUD, Indications_and_Usage_INFUG,
 Indications_and_Usage_IRESS, Indications_and_Usage_KEYTR, Indications_and_Usage_KRAZA,
 Indications_and_Usage_LIBTA, Indications_and_Usage_LORBR, Indications_and_Usage_LUMAK,
 Indications_and_Usage_LURB, Indications_and_Usage_MEKIN, Indications_and_Usage_METH,
 Indications_and_Usage_MVASI, Indications_and_Usage_OPDIV, Indications_and_Usage_PORTR,
 Indications_and_Usage_RAMUC, Indications_and_Usage_RETEV, Indications_and_Usage_ROZLY,
 Indications_and_Usage_RYBRE, Indications_and_Usage_SELPE, Indications_and_Usage_SOTOR,
 Indications_and_Usage_TABRE, Indications_and_Usage_TAFIN, Indications_and_Usage_TAGRIS,
 Indications_and_Usage_TAXOT, Indications_and_Usage_TECEN, Indications_and_Usage_TEPME,
 Indications_and_Usage_TOPO, Indications_and_Usage_TRAME, Indications_and_Usage_TREME,
 Indications_and_Usage_TREXA, Indications_and_Usage_VINOR, Indications_and_Usage_VIZIM,
 Indications_and_Usage_XALKO, Indications_and_Usage_YERVO, Indications_and_Usage_ZIRAB,
 Indications_and_Usage_ZYKAD, Limited_Stage_SCLC, Living_with_LC_LC, Location_LC, Lurbinectedin_,
 Marijuana_Smoking_LC, Medications_LC, Methotrexate_Sodium_, Never-Smokers_LC, Non-Small_Cell_LC, Non-
 Small_Cell_LC_NSCLC, Non-Small_Cell_Lung_Cancer, Non-Small_Cell_Medication_LC_, Non-Smokers_LC, Non-
 Smokers_NSCLC, Non-Smokers_SCLC, Nutrition_LC, Occupational_Exposure,
 Physical_Activity_For_Mitigation_of_LC, Physical_Activity_For_Prevention_Of_LC, Preventative_habits_LC,
 Quitting/Not_Smoking_LC, Radiation_Exposure_LC, Ramucirumab_, Recurring_LC_NSCLC, Recurring_LC_SCLC,
 Rural_LC, Second-hand_Smoke_LC, Secondhand_Smoke_LC, Selpercatinib_, Sensor_Factors_LC,
 Size_of_the_community_LC, Sleep_LC, Small_Cell_LC, Small_Cell_LC_SCLC, Small_Cell_Lung_Cancer,
 Small_Cell_Medication_LC_, Smoke_LC, Smokers_LC, Smokers_NSCLC, Smokers_SCLC, Smoking_LC,
 Smoking_Marijuana_LC, Smoking_Other_Drugs_LC, Smoking_Tobacco_LC, Sotorasib_, Stage_0_NSCLC,
 Stage_1_NSCLC, Stage_1_SCLC, Stage_2_NSCLC, Stage_3A_NSCLC, Stage_3B_NSCLC, Stage_4_NSCLC,
 Support_Groups_LC, Symptoms_and_Tests_LC, Symptoms_NSC, Symptoms_SC, Tests_NSC, Tests_SC,

Tobacco_Smoking, Tobacco_Smoking_LC, Topotecan_Hydrochloride_, Trametinib_Dimethyl_Sulfoxide,
 Treatment_Regimens_LC, Treatments_LC, Tremelimumab-actl_, Urban_LC,
 Use_in_Specific_Populations_ABRAX, Use_in_Specific_Populations_ADAGR, Use_in_Specific_Populations_AFATI,
 Use_in_Specific_Populations_AFINI, Use_in_Specific_Populations_AFINIT, Use_in_Specific_Populations_ALECE,
 Use_in_Specific_Populations_ALIMT, Use_in_Specific_Populations_ALUNB, Use_in_Specific_Populations_ALYMS,
 Use_in_Specific_Populations_AMIVA, Use_in_Specific_Populations_ATEZO, Use_in_Specific_Populations_AVAST,
 Use_in_Specific_Populations_BRIGA, Use_in_Specific_Populations_CAPMA, Use_in_Specific_Populations_CEMIP,
 Use_in_Specific_Populations_CYRAM, Use_in_Specific_Populations_DOXOR,
 Use_in_Specific_Populations_DURVA, Use_in_Specific_Populations_ENHER,
 Use_in_Specific_Populations_ENTRE, Use_in_Specific_Populations_ERLOT, Use_in_Specific_Populations_ETOP,
 Use_in_Specific_Populations_ETOPO, Use_in_Specific_Populations_EXKIV, Use_in_Specific_Populations_GAVRE,
 Use_in_Specific_Populations_GEFIT, Use_in_Specific_Populations_GEMZA, Use_in_Specific_Populations_GILOT,
 Use_in_Specific_Populations_HYCAM, Use_in_Specific_Populations_IMFIN, Use_in_Specific_Populations_IMJUD,
 Use_in_Specific_Populations_INFUG, Use_in_Specific_Populations_IRESS, Use_in_Specific_Populations_KEYTR,
 Use_in_Specific_Populations_KRAZA, Use_in_Specific_Populations_LIBTA, Use_in_Specific_Populations_LORBR,
 Use_in_Specific_Populations_LUMAK, Use_in_Specific_Populations_LURB, Use_in_Specific_Populations_MEKIN,
 Use_in_Specific_Populations_METH, Use_in_Specific_Populations_MVASI, Use_in_Specific_Populations_OPDIV,
 Use_in_Specific_Populations_PORTR, Use_in_Specific_Populations_RAMUC, Use_in_Specific_Populations_RETEV,
 Use_in_Specific_Populations_ROZLY, Use_in_Specific_Populations_RYBRE, Use_in_Specific_Populations_SELPE,
 Use_in_Specific_Populations_SOTOR, Use_in_Specific_Populations_TABRE, Use_in_Specific_Populations_TAFIN,
 Use_in_Specific_Populations_TAGRIS, Use_in_Specific_Populations_TAXOT,
 Use_in_Specific_Populations_TECEN, Use_in_Specific_Populations_TEPME, Use_in_Specific_Populations_TOPO,
 Use_in_Specific_Populations_TRAME, Use_in_Specific_Populations_TREME, Use_in_Specific_Populations_TREXA,
 Use_in_Specific_Populations_VINOR, Use_in_Specific_Populations_VIZIM, Use_in_Specific_Populations_XALKO,
 Use_in_Specific_Populations_YERVO, Use_in_Specific_Populations_ZIRAB, Use_in_Specific_Populations_ZYKAD,
 Vinorelbine_Tartrate_, Warnings_and_Precautions_ABRAX, Warnings_and_Precautions_ADAGR,
 Warnings_and_Precautions_AFATI, Warnings_and_Precautions_AFINI, Warnings_and_Precautions_AFINIT,
 Warnings_and_Precautions_ALECE, Warnings_and_Precautions_ALIMT, Warnings_and_Precautions_ALUNB,
 Warnings_and_Precautions_ALYMS, Warnings_and_Precautions_AMIVA, Warnings_and_Precautions_ATEZO,
 Warnings_and_Precautions_AVAST, Warnings_and_Precautions_BRIGA, Warnings_and_Precautions_CAPMA,
 Warnings_and_Precautions_CEMIP, Warnings_and_Precautions_CYRAM, Warnings_and_Precautions_DOXOR,
 Warnings_and_Precautions_DURVA, Warnings_and_Precautions_ENHER, Warnings_and_Precautions_ENTRE,
 Warnings_and_Precautions_ERLOT, Warnings_and_Precautions_ETOP, Warnings_and_Precautions_ETOPO,
 Warnings_and_Precautions_EXKIV, Warnings_and_Precautions_GAVRE, Warnings_and_Precautions_GEFIT,
 Warnings_and_Precautions_GEMZA, Warnings_and_Precautions_GILOT, Warnings_and_Precautions_HYCAM,
 Warnings_and_Precautions_IMFIN, Warnings_and_Precautions_IMJUD, Warnings_and_Precautions_INFUG,
 Warnings_and_Precautions_IRESS, Warnings_and_Precautions_KEYTR, Warnings_and_Precautions_KRAZA,
 Warnings_and_Precautions_LIBTA, Warnings_and_Precautions_LORBR, Warnings_and_Precautions_LUMAK,
 Warnings_and_Precautions_LURB, Warnings_and_Precautions_MEKIN, Warnings_and_Precautions_METH,
 Warnings_and_Precautions_MVASI, Warnings_and_Precautions_OPDIV, Warnings_and_Precautions_PORTR,
 Warnings_and_Precautions_RAMUC, Warnings_and_Precautions_RETEV, Warnings_and_Precautions_ROZLY,
 Warnings_and_Precautions_RYBRE, Warnings_and_Precautions_SELPE, Warnings_and_Precautions_SOTOR,
 Warnings_and_Precautions_TABRE, Warnings_and_Precautions_TAFIN, Warnings_and_Precautions_TAGRIS,
 Warnings_and_Precautions_TAXOT, Warnings_and_Precautions_TECEN, Warnings_and_Precautions_TEPME,
 Warnings_and_Precautions_TOPO, Warnings_and_Precautions_TRAME, Warnings_and_Precautions_TREME,
 Warnings_and_Precautions_TREXA, Warnings_and_Precautions_VINOR, Warnings_and_Precautions_VIZIM,
 Warnings_and_Precautions_XALKO, Warnings_and_Precautions_YERVO, Warnings_and_Precautions_ZIRAB,
 Warnings_and_Precautions_ZYKAD

OWL HTML inside